Papulopustular Rosacea

Journey Medical Corporation’s efforts to launch a new rosacea drug have received a boost of up to $20 million as the company has entered into a credit facility with an affiliate of SWK Holdings Corporation.

Two phase 3 clinical trials evaluating DFD-29 for the treatment of adults with papulopustular rosacea achieved positive topline results, according to a Journey Medical Corporation press release.

Journey Medical Corporation announced positive, topline results from its phase 1 clinical trial evaluating the impact of DFD-29 on the microbial flora of healthy adults, according to a company press release.

Journey Medical Corporation announced that it has completed enrollment in its phase 3 clinical program evaluating the safety and efficacy of DFD-29 for the treatment of papulopustular rosacea, according to a company press release.

Journey Medical Corporation announced that DFD-29 has demonstrated low systemic exposure in the treatment of papulopustular rosacea based on an ongoing phase 3 study, according to a company press release.

Erythematotelangiectatic and papulopustular rosacea were found to be the chronic skin condition’s most common subtypes, according to a systematic review and meta-analysis.

Oral sarecycline was effective for the treatment of patients with papulopustular rosacea, according to a presentation at the South Beach Symposium Medical Dermatology Summit.

Patients treated with secukinumab for papulopustular rosacea saw significant improvements in quality of life and reduction of severity markers, according to a study presented at the American Academy of Dermatology virtual meeting.